1 Clinical and immunologic features in severe and moderate forms of Coronavirus Disease

- 2 2019
- 3 Guang Chen^{1*}, Di Wu^{1*}, Wei Guo^{1*}, Yong Cao^{2*}, Da Huang^{1†}, Hongwu Wang^{1†}, Tao Wang^{2†},
- 4 Xiaoyun Zhang^{1†}, Huilong Chen¹, Haijing Yu¹, Xiaoping Zhang¹, Minxia Zhang³, Shiji Wu³,
- 5 Jianxin Song¹, Tao Chen¹, Meifang Han¹, Shusheng Li⁴, Xiaoping Luo⁵, Jianping Zhao², Qin
- 6 Ning¹
- 7
- ¹Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College,
- 9 Huazhong University of Science and Technology, Wuhan, China
- ¹⁰ ²Department of Respiratory Disease, Tongji Hospital, Tongji Medical College, Huazhong
- 11 University of Science and Technology, Wuhan, China
- ³Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong
- 13 University of Science and Technology, Wuhan, China
- ⁴ Department of Emergency Medicine, Tongji Hospital, Huazhong University of Science and
- 15 Technology, Wuhan, China
- ⁵Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of
- 17 Science and Technology, Wuhan, China
- 18
- 19 * [†]Contributed equally.
- 20
- 21 Corresponding author:
- 22 Qin Ning, MD, PhD
- 23 Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College,
- 24 Huazhong University of Science and Technology, Wuhan, China
- 25 No. 1095, Jiefang Avenue, Wuhan, China. 430030
- 26 Email: qning@vip.sina.com
- 27 Phone: +86 27 8366 2391
- 28 Fax: +86 27 8366 2391
- 29

- 30 Email:
- 31 Guang Chen: widechain@163.com
- 32 Di Wu: woody_1984@163.com
- 33 Wei Guo: 294571240@qq.com
- 34 Yong Cao: 2677877@qq.com
- 35 Da Huang: 413706477@qq.com
- 36 Hongwu Wang: hongwuwang@126.com
- 37 Tao Wang: wt7636@126.com
- 38 Xiaoyun Zhang: 403065840@qq.com
- 39 Huilong Chen: huilong_chen@126.com
- 40 Haijing Yu: 463104640@qq.com
- 41 Xiaoping Zhang: 503125569@qq.com
- 42 Minxia Zhang: 764180047@qq.com
- 43 Shiji Wu: 7212460@qq.com
- 44 Jianxin Song: jxsong@tjh.tjmu.edu.cn
- 45 Tao Chen: chentao_tjh@vip.sina.com
- 46 Meifang Han: 156755182@qq.com
- 47 Shusheng Li: shushengli16@sina.com
- 48 Xiaoping Luo: xpluo888@sina.com
- 49 Jianping Zhao: Zhaojp88@126.com
- 50 Qin Ning: qning@vip.sina.com
- 51
- 52

53 Abstract

60

Background Since late December, 2019, an outbreak of pneumonia cases caused by the
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, and
continued to spread throughout China and across the globe. To date, few data on immunologic
features of Coronavirus Disease 2019 (COVID-19) have been reported.
Methods In this single-centre retrospective study, a total of 21 patients with pneumonia who
were laboratory-confirmed to be infected with SARS-CoV-2 in Wuhan Tongji hospital were

clinical, laboratory, radiological features were compared between 11 severe cases and 10moderate cases.

included from Dec 19, 2019 to Jan 27, 2020. The immunologic characteristics as well as their

63 **Results** Of the 21 patients with COVID-19, only 4 (19%) had a history of exposure to the 64 Huanan seafood market. 7 (33.3%) patients had underlying conditions. The average age of 65 severe and moderate cases was 63.9 and 51.4 years, 10 (90.9%) severe cases and 7 (70.0%) 66 moderate cases were male. Common clinical manifestations including fever (100%, 100%), 67 cough (70%, 90%), fatigue (100%, 70%) and myalgia (50%, 30%) in severe cases and 68 moderate cases. PaO2/FiO2 ratio was significantly lower in severe cases (122.9) than 69 moderate cases (366.2). Lymphocyte counts were significantly lower in severe cases (0.7 \times 70 $10\Box/L$) than moderate cases ($1.1 \times 10\Box/L$). Alanine aminotransferase, lactate dehydrogenase 71 levels, high-sensitivity C-reactive protein and ferritin were significantly higher in severe cases 72 (41.4 U/L, 567.2 U/L, 135.2 mg/L and 1734.4 ug/L) than moderate cases (17.6 U/L, 234.4 73 U/L, 51.4 mg/L and 880.2 ug /L). IL-2R, TNF- α and IL-10 concentrations on admission were 74 significantly higher in severe cases (1202.4 pg/mL, 10.9 pg/mL and 10.9 pg/mL) than 75 moderate cases (441.7 pg/mL, 7.5 pg/mL and 6.6 pg/mL). Absolute number of total T 76 lymphocytes, CD4⁺T cells and CD8⁺T cells decreased in nearly all the patients, and were 77 significantly lower in severe cases (332.5, 185.6 and $124.3 \times 10^6/L$) than moderate cases 78 (676.5, 359.2 and 272.0 \times 10⁶/L). The expressions of IFN- γ by CD4⁺T cells tended to be 79 lower in severe cases (14.6%) than moderate cases (23.6%).

80 Conclusion The SARS-CoV-2 infection may affect primarily T lymphocytes, particularly
 81 CD4⁺T cells, resulting in significant decrease in number as well as IFN-γ production, which

- 82 may be associated with disease severity. Together with clinical characteristics, early
- 83 immunologic indicators including diminished T lymphocytes and elevated cytokines may
- 84 serve as potential markers for prognosis in COVID-19.
- 85
- 86 Keywords: SARS-CoV-2; COVID-19; cytokines; lymphocytes; IFN-γ
- 87

88 Introduction

89 Coronaviruses (CoV) are a large family of respiratory viruses that can cause diseases ranging 90 from the common cold to the Middle-East Respiratory Syndrome (MERS) and the Severe Acute Respiratory Syndrome (SARS)^{1,2}, both of which are zoonotic in origin and induce fatal 91 92 lower respiratory tract infection as well as extrapulmonary manifestations. The new 93 coronavirus, designated as the severe acute respiratory syndrome coronavirus 2 94 (SARS-CoV-2), is a member of Beta-CoV lineage B, which was first identified in Wuhan, 95 China by the Chinese Center for Disease Control and Prevention (CDC)^{3,4}. Recent reports 96 have provided evidence for person to person transmission of the SARS-CoV-2 in family and hospital settings ^{5,6}. As of Feb 1, 2020, the number of SARS-CoV-2 cases globally had 97 98 eclipsed 14000, exceeding the total number of SARS cases during the 2003 epidemic, and 99 more than 300 people had now died. The outbreak of SARS-CoV-2-induced Coronavirus 100 Disease 2019 (COVID-19) has put health authorities on high alert in China and across the 101 globe.

102 It has been revealed that SARS-CoV-2 has a genome sequence 75% to 80% identical to the 103 SARS-CoV and has more similarities to several bat coronaviruses³. Both clinical and 104 epidemiological features of patients with COVID-19 have recently been reported, 105 demonstrating that the SARS-CoV-2 infection can cause clusters of severe respiratory illness 106 with clinical presentations greatly resembling SARS-CoV, leading to ICU admission and high 107 mortality'. Clinical manifestations have included fever, fatigue, dry cough, shortness of breath, 108 and acute respiratory distress syndrome (ARDS). Additionally, a study of the first 41 109 laboratory-confirmed cases with COVID-19 showed that 63% of patients had lymphopenia, 110 and cytokine storm could be associated with disease severity. However, little is known about 111 immunologic features between severe and moderate forms of COVID-19⁷.

112 In this study, we performed a comprehensive evaluation of characteristics of 21 patients with 113 COVID-19 admitted to Tongji Hospital, Wuhan. We aimed to compare the clinical and 114 immunologic features between severe cases and moderate cases. These findings will help us 115 extend our understanding of the pathophysiological mechanism of the SARS-CoV-2 infection.

116 **Patients and methods**

117 Study participants

From late Dec 19, 2019 to Jan 27, 2020, a total of 21 cases who initially presented with fever or respiratory symptoms, with pulmonary infiltrates on chest computed tomography (CT) scans in isolation ward of Department of Infectious Disease, Tongji hospital were later confirmed to be infected with the novel coronavirus by the local health authority. Four cases had a history of exposure to the Huanan seafood market.

We retrospectively evaluated and analyzed the medical history, physical examination, and hematological, biochemical, radiological, microbiological and immunological evaluation results obtained from these 21 patients with COVID-19. Epidemiological, clinical, laboratory, and radiological characteristics and treatment as well as outcomes data were obtained from electronic medical records. The data collection forms were reviewed independently by two researchers.

129 The patients with SpO2 \leq 93% or respiratory rates \geq 30 per min were classified as having 130 severe COVID-19, those without above-mentioned signs as moderate cases.

Considering the emergence of COVID-19 cases during the influenza season, oseltamivir (orally 75 mg twice daily) and antibiotics (oral and intravenous) were empirically administered. Corticosteroid therapy (methylprednisolone) was given concomitantly to some patients with COVID-19 by physicians. Oxygen support including nasal cannula and non-invasive mechanical ventilation was provided to the patients according to the severity of hypoxemia. After being identified as having laboratory-confirmed SARS-CoV-2 infection, these patients were transferred to the designated hospital.

The study was approved by the Institutional Review Board of Tongji Hospital, Tongji MedicalCollege, Huazhong University of Science and Technology.

140

141 Complication definitions

142 ARDS and shock were defined according to the interim guidance of WHO for novel
143 coronavirus⁸.

Hypoxemia was defined as arterial oxygen tension (PaO2) over inspiratory oxygen fraction(FIO2) of less than 300 mm Hg.

Acute kidney injury was identified and classified on the basis of the highest serum creatinine
level or urine output criteria according to the kidney disease improving global outcomes
classification.

Acute liver injury was defined as jaundice with a total bilirubin level of $\geq 3 \text{ mg/dl}$ and an acute increase in alanine aminotransferase of at least five times the upper limit of the normal range and/or an increase in alkaline phosphatase of at least twice the upper limit of the normal range.

153 Cardiac injury was diagnosed if serum levels of cardiac biomarkers were > the 99th percentile
154 upper reference limit, or new abnormalities were shown in electrocardiography and
155 echocardiography.

156 Secondary infection including bacteria and fungus was diagnosed if the patients had clinical 157 symptoms or signs of nosocomial pneumonia or bacteremia, and was combined with a 158 positive culture of a new pathogen from a respiratory tract specimen or from blood samples 159 taken ≥48 h after admission.

160

161 Laboratory measurements

162 Respiratory pathogen detection

163 Respiratory specimens were collected by local CDC and then shipped to designated 164 authoritative laboratories to detect the SARS-CoV-2. The presence of SARS-CoV-2 in 165 respiratory specimens was detected by next-generation sequencing or real-time RT-PCR 166 methods. The primers and probe target to envelope gene of CoV were used and the sequences 167 were as follows: forward primer 5'-TCAGAATGCCAATCTCCCCAAC-3'; reverse primer 168 5'-AAAGGTCCACCCGATACATTGA-3'; and the probe 169 5'CY5-CTAGTTACACTAGCCATCCTTACTGC-3'BHQ1. Conditions for the amplifications 170 were 50°C for 15 min, 95°C for 3 min, followed by 45 cycles of 95°C for 15 s and 60°C for 171 30 s.

172

173 Clinical laboratory measurements

174 Initial clinical laboratory investigation included a complete blood count, serum biochemical

175 test (including liver and renal function, creatine kinase, lactate dehydrogenase, and 176 electrolytes), coagulation profile, as well as immunological test (including serum cytokines, 177 peripheral immune cells subsets and the expression of IFN- γ by immune cells). Respiratory 178 specimens, including nasal and pharyngeal swabs, or sputum were tested to exclude evidence 179 of other virus infection, including influenza, respiratory syncytial virus, avian influenza, 180 parainfluenza virus and adenovirus using real-time RT-PCR assays approved by the China 181 Food and Drug Administration. Routine bacterial and fungal examinations were also 182 performed.

183

184 Cytokine measurement

To explore the impact of SARS-CoV-2 on the secretion of cytokines in the early phase of the infection, plasma cytokines including IL-1 β , IL-2R, IL-6, IL-8 (also known as CXCL8), IL-10, and TNF- α were measured using the sandwich enzyme-linked immune-sorbent assay (ELISA) method by micro-ELISA autoanalyser (Diasorin Etimax 3000, Germany) for all patients according to the manufacturer's instructions. The first initial blood samples were drawn shortly after hospital admission.

191

192 Proportions analysis of peripheral blood immunological indicators

193The proportions and numbers of NK, $CD4^+T$, $CD8^+T$, Treg and B cells, and the expression of194cell surface markers as well as IFN- γ expression by $CD4^+T$, $CD8^+T$ and NK cells were studied195in these patients with laboratory-confirmed SARS-CoV-2 infection who were reported by the196localhealthauthority.

197 PE-CD28/PE•CY7-CD8/PerCP-CD45/APC-HLADR/APC•CY7-CD3/V450-CD4,

198 FITC-CD45RA/PE-CD45RO/PE•CY7-CD127/PerCP-CD45/APC-CD25/APC•CY7-CD3/V4
 199 50-CD4,

200 FITC-CD3/PE-CD8/PE•CY7-CD56/PerCP-CD45/APC-IFN-γ/APC•CY7-CD3/V450-CD4

multiple-color anti-human monoclonal antibodies (mAbs) combination reagents and matched
 isotype controls were used to determine the peripheral immune cell subsets within 2 days
 after admission. Peripheral blood mononuclear cells (PBMCs) were isolated immediately

from fresh blood and subjected to antibody staining followed by flow cytometry. All reagents were purchased from Becton, Dickinson, and Company (BD, Franklin Lakes, USA). Cell surface antigen staining for flow cytometry was conducted according to the standard procedure of the BD Pharmingen protocol. All samples were detected by BD FACS Canto II Flow Cytometry System and analyzed with the BD FACS Diva Software.

209

210 Statistical analysis

211 Continuous variables were expressed as mean (S.D.) and compared with the Mann-Whitney

212 U test; categorical variables were expressed as number (%) and compared by χ^2 test or

213 Fisher's exact test between moderate and severe case groups. A two-sided α of less than 0.05

- 214 was considered statistically significant. Statistical analyses were done using the SAS software,
- 215 version 9.4.

217 Results

Patient demographics and baseline characteristics of severe and moderate forms ofCOVID-19

220 By Jan 22, 2020, a total of 21 admitted hospital patients with pneumonia were identified as 221 laboratory-confirmed SARS-CoV-2 infection in Wuhan Tongji hospital. Of these patients, 222 only four patients including a familial cluster of three confirmed cases had direct exposure to 223 Huanan seafood market. 11 (52.4%) patients with SpO2 \leq 93% or respiratory rates \geq 30 per min 224 who required high-flow nasal cannula or non-invasive mechanical ventilation using the 225 Bilevel Positive Airway Pressure (BiPAP) mode to correct hypoxemia, were classified as 226 having severe COVID-19, whereas 10 (47.6%) patients without above-mentioned signs as 227 moderate cases. 10 (90.9%) of severe cases and 7 (70%) of moderate cases were male (table 228 1). The mean age of the severe cases (63.9 years) was significantly older than moderate cases 229 (51.4 years). 90.9% of severe cases were above 50 years old, which was more frequent than 230 that of moderate cases (50%). 5 (45.5%) of severe cases and 2 (20%) moderate cases had 231 underlying diseases. Of 7 patients with underlying diseases, four patients had hypertension, 232 two had diabetes, and one had both hypertension and diabetes. The mean time from onset of 233 symptoms to first hospital admission was 7.3 days in severe cases and 5.5 days in moderate 234 cases.

Four of eleven severe cases died at an average of 20 days after the onset of the illness. Of these four fatal cases, all of them were male and had age over 50 years old, and two had hypertension. Mean age of fatal cases were 67.5 years old. Three of the fatal cases had PaO2/FiO2 ratio \leq 100 on admission.

Excluding one comatose patient without a clear history (classified as severe case), the most common clinical manifestations at onset of illness include fever (100% of total cases), cough (70% of severe cases, 90% of moderate cases), fatigue (100% of severe cases, 70% of moderate cases) and myalgia (50% of severe cases, 30% of moderate cases). Less common symptoms include sputum production (20% of severe cases, 30% of moderate cases), diarrhea (10% of severe cases, 30% of moderate cases), headache (10% of severe cases, 10% of moderate cases) and hemoptysis (10% of severe cases). All the severe cases developed

246 dyspnea, and nine of them had SpO2<93% even with high-flow nasal cannula, who were then 247 ventilated using the BiPAP mode to treat hypoxemia. The mean duration from illness onset to 248 dyspnea was 8.6 days. Arterial blood gas (ABG) test was performed in 10 patients on 249 admission (six severe and four moderate cases). Of them, PaO2/FiO2 ratio was significantly 250 lower in severe cases (122.9 mmHg) than moderate cases (366.2 mmHg). Three severe cases 251 had PaO2/FiO2 ratio \leq 100, indicating severe ARDS.

252

253 Laboratory findings and CT scans of severe and moderate forms of COVID-19

The routine blood tests on admission of three (30%) moderate cases showed mild leucopenia (white blood cell count (WBC) < 4×10 \square/L). WBC counts were normal or slightly increased in all the severe cases. Both WBC and neutrophil counts were significantly higher in severe cases (9.2 × 10 \square/L and 8.0 × 10 \square/L) than moderate cases (4.7 × 10 \square/L and 3.1 × 10 \square/L). Whereas lymphocyte counts were significantly lower in severe cases (0.7 × 10 \square/L) than moderate cases (1.1 × 10 \square/L). Lymphopenia (lymphocyte count <0.8 × 10 \square/L) was found in 8 (72.7%) severe cases and only 1 (10.0%) moderate cases (table 2).

Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were significantly higher in severe cases (41.4 U/L and 51.0 U/L) than moderate cases (17.6 U/L and 24.2 U/L). Albumin concentrations were significantly lower in severe cases (31.5g/L) than moderate cases (37.6g/L). Levels of lactate dehydrogenase (LDH) were significantly higher in severe cases (567.2 U/L) than moderate cases (234.4 U/L).

Concentrations of serum high-sensitivity C-reactive protein (hsCRP) and ferritin on admission were significantly elevated in severe cases (135.2 mg/L and 1734.4 ug/L) than moderate cases (51.4 mg/L and 880.2 ug /L). Serum levels of procalcitonin on admission tended to be higher in severe cases (0.5 ng/mL) than moderate cases (0.1 ng/mL). Activated partial thromboplastin time (APTT) on admission was significantly shorter in severe cases (36.2s) than moderate cases (44.6s). D-dimer levels on admission were markedly greater in severe cases (8.2 ug/mL) than moderate cases (0.4 ug/mL).

Interstitial lung abnormalities were observed in chest CT scans of all patients on admission.
Of the 21 patients, 10 (90.1%) severe cases and 7 (70%) moderate cases had bilateral

involvement on admission (table 2). Later on, only one patient with moderate COVID-19
remained unilateral involvement. The typical findings of chest CT images of severe
COVID-19 on admission showed bilateral ground glass opacity and subsegmental areas of
consolidation (figure 1A), then progressed rapidly with mass shadows of high density in both
lungs (figure 1B). Whereas the representative chest CT findings of moderate COVID-19
showed bilateral ground glass opacity (figure 1C). Later chest CT images revealed bilateral
ground-glass opacity had been resolved (figure 1D).

282

283 Immunologic features of severe and moderate forms of COVID-19

284 Evaluation of plasma cytokines revealed that IL-2R, IL-6, IL-10, and TNF- α concentrations 285 on admission were moderately elevated in the majority of severe cases (88.9%, 88.9%, 77.8%, 286 and 88.9%), but only mildly increased (14.3%, 71.4%, 28.6%, and 42.9%) or remained within 287 the normal range in moderate cases (table 3). IL-8 concentrations were elevated in few 288 patients (22.2% severe cases, 14.3% moderate cases). IL-1 β concentrations were undetectable 289 (<5pg/mL) in nearly all the patients with either severe or moderate COVID-19. IL-2R, TNF- α 290 and IL-10 concentrations on admission were significantly higher in severe cases (1202.4 291 pg/mL, 10.9 pg/mL and 10.9 pg/mL) than moderate cases (441.7 pg/mL, 7.5 pg/mL and 6.6 292 pg/mL).

293 Preliminary analysis of circulating immune cells subsets showed that absolute number of total 294 T lymphocytes, CD4⁺T cells and CD8⁺T cells decreased in the majority of patients with either 295 severe (100%, 100% and 87.5%) or moderate COVID-19 (83.3%, 100% and 83.3%), and 296 total T lymphocytes, CD4⁺T cells and CD8⁺T cells counts were reduced more profoundly in 297 severe cases (332.5, 185.6 and 124.3 \times 10⁶/L) than moderate cases (676.5, 359.2 and 272.0 \times 298 10° /L) (figure 2A, 2B). More severe cases (100%) had the proportion of HLA-DR⁺ expression 299 on CD8⁺T cells (of > 35%) than moderate cases (25%). Reduction of B cells and NK cells 300 counts tended to be more frequent in severe cases (37.5% and 75%) than moderate cases (16.7% 301 and 33.3%), whereas the proportion of B cells was significantly higher in severe cases (26.5%) 302 than moderate cases (12.0%). This could be partly due to the more significant decrease of T 303 lymphocytes in severe cases. In addition, six (75.0%) of eight severe cases showed a broad,

304 significant decrease in all the lymphocytes subsets excluding B cells, with total T 305 lymphocytes counts below 400×10^6 /L, CD8⁺T cells counts below 150×10^6 /L, and NK cells 306 counts below 77×10^6 /L. Of these six patients, three (50%) eventually died.

307 Moreover, the frequencies of Treg (CD4⁺CD25⁺CD127^{low+}) and CD45RA⁺Treg decreased in 308 nearly all the severe (60% and 100%) and moderate cases (100% and 100%), with 309 CD45RA⁺Treg decreased more profoundly in severe cases (0.5%) than moderate cases (1.1%). 310 The expressions of IFN- γ by CD4⁺T, CD8⁺T and NK cells were decreased in some patients 311 with severe (50%, 16.7% and 16.7%) or moderate COVID-19 (14.3%, 0% and 14.3%). The 312 expressions of IFN- γ by CD4⁺T cells tended to be lower in severe cases (14.6%) than 313 moderate cases (23.6%) (figure 2C).

314

315 Complications and clinical outcomes of COVID-19

316 As for complications, nine (81.8%) severe cases and one (10%) moderate case developed 317 ARDS, among them, three (27.3%) severe cases had confirmed severe ARDS by ABG test 318 with PaO2/FiO2 \leq 100. One case developed multiple organ dysfunction syndrome (MODS), 319 including acute kidney injury, cardiac injury and heart failure as well as pulmonary 320 encephalopathy prior to admission. Another patient developed acute liver injury and 321 disseminated intravascular coagulation in a short time. These two patients died soon 322 afterwards. One patient with severe COVID-19 developed acute liver injury and was in 323 recovery and discharged after a three-week hospitalization, with extracorporeal membrane 324 oxygenation (ECMO) support. The chest CT scan afterwards showed improvement of 325 bilateral ground-glass opacity and subsegmental areas of consolidation.

Of 21 patients, nine (42.9%) required non-invasive ventilation. 19 (90.5%) patients received antiviral therapy (oseltamivir and ganciclovir). All patients were given empirical antimicrobial treatment (moxifloxacin or cefoperazone-sulbactam). In Addition, most patients (85.7%) were administered corticosteroids (methylprednisolone). As of Feb 2, 2020, 4 (36.4%) of 11 severe cases and none (0.0%) of the moderate cases have died, the average days from illness onset to death was 20 days. One severe and one moderate case have recovered. Patients were transferred to the designated hospital after being identified as having

333 laboratory-confirmed SARS-CoV-2 infection.

335 Discussion

336 This is the first preliminary study evaluating descriptively the immunologic characteristics of 337 patients with laboratory-confirmed SARS-CoV-2 infection. Both clinical and epidemiological 338 features of patients with COVID-19 have recently been reported^{5-7,9}. However, there is 339 insufficient knowledge of pathophysiological parameters as well as immunologic indicators to 340 understand the mechanism involved in COVID-19. Consistent with previous reports', in this 341 present study, a male predominance in the incidence of COVID-19 has been noted similar to 342 that of SARS-CoV, indicating males are more susceptible to SARS-CoV-2 infection than 343 females. Older males (>50 years old), in particular those with chronic comorbidities may be 344 more likely to develop severe COVID-19, and associated with a high mortality (28.6% of 345 males aged >50 years old with comorbidities). The most common clinical manifestations at 346 onset of illness included fever, cough, fatigue and myalgia. Severe cases were more likely to 347 have dyspnea and significantly lower PaO2/FiO2, and to develop ARDS. In terms of 348 laboratory finding, leukocytosis ($\geq 10 \times 10 \square/L$) but lymphopenia ($< 0.8 \times 10 \square/L$) were more 349 common in severe cases than moderate cases. ALT, LDH, D-dimer and inflammatory markers 350 including hsCRP and ferritin were significantly higher in severe cases than moderate cases. 351 Plasma concentrations of both pro-inflammatory cytokines and anti-inflammatory cytokines, 352 including IL-2R, TNF- α and IL-10 increased in the majority of severe cases and was 353 significantly higher than did those in moderate cases, suggesting cytokine storms might be 354 associated with disease severity.

355 Additionally, we also noted that SARS-CoV-2 infection can cause a significant reduction in 356 peripheral blood lymphocytes and T cell subsets. Although the proportions of T cells subsets 357 in peripheral blood remained within the normal range in most patients, the prevalence of 358 decreasing CD4⁺T cell counts and CD8⁺T cell counts was considerably high in both severe 359 and moderate cases. It is notable that both the proportion and number of B cells were not 360 frequently decreased in these patients. More importantly, the number of CD4⁺T cells and 361 CD8⁺T cells was markedly lower in severe cases than moderate cases. Albeit diminished 362 $CD8^+$ T cells, the proportion of HLA-DR⁺ expression on $CD8^+$ T cells over 35% was more 363 common in severe cases than those of moderate cases. The expression of HLA-DR on human

364 T cells has been regarded primarily as a marker of activated T cells. However, It has been 365 recently indicated that CD8⁺ HLA-DR⁺ T cells constitute to a natural subset of Treg and may 366 exert suppressive effect involving CTLA-4 signaling between neighboring T cells¹⁰. Besides, 367 six out of eight severe cases and none of moderate cases with available immunologic data 368 exhibited a broad, significant decline in all the lymphocyte subsets excluding B cells, with 369 total T lymphocyte counts below 400×10^6 /L, CD8⁺T cells below 150×10^6 /L, and NK cells 370 below $< 77 \times 10^6$ /L, of these six patients, three (50%) eventually died, indicating that 371 SARS-CoV-2 infected patients with severe lymphopenia have high-risk of developing severe 372 COVID-19 and extremely high mortality. Moreover, the production of IFN- γ by CD4⁺T cells 373 but not CD8⁺T cells or NK cells tended to be lower in severe cases than moderate cases. 374 These data suggest that SARS-CoV-2 infection may affect primarily T lymphocytes, 375 particularly CD4⁺T cells, resulting in diminished number as well as their IFN- γ production, 376 which might be correlated with disease severity of COVID-19.

377 CD4⁺ T cells play a pivotal role in regulating immune responses, orchestrating the deletion 378 and amplification of immune cells, especially $CD8^+$ T cells. $CD4^+$ T cells facilitate 379 virus-specific antibody production via the T-dependent activation of B cells¹¹. However, CD8⁺ 380 T cells exert their effects mainly through two mechanisms, cytolytic activities against target 381 cells or cytokines secretion, including IFN- γ , TNF- α , and IL-2 as well as many chemokines¹². 382 The production of IFN- γ is essential for the resistance against infection of various pathogens such as virus, bacteria, and parasite¹³. As a major source of IFN- γ , the ability of T cells to 383 384 respond to infection is part of the adaptive immune response and takes days to develop a 385 prominent IFN-y response.

The roles of T cell responses in the context of SARS-CoV and MERS-CoV infection have been previously studied. Likewise, patients who survived SARS-CoV and MERS-CoV infections usually had better immune responses than those who did not¹⁴. The immune system plays an important role in both diseases, but it is differentially affected by the two viruses¹⁵. A study in SARS-CoV mice model has shown that depletion of CD8⁺ T cells at the time of infection does not affect viral replication or clearance. However, depletion of CD4⁺ T cells leads to an enhanced immune-mediated interstitial pneumonitis and delayed clearance of

393 SARS-CoV from the lungs, demonstrating the vital role of CD4⁺ T but not CD8⁺ T cells in 394 primary SARS-CoV infection ¹⁶. A Chinese study in SARS-CoV-infected patients has 395 demonstrated that the majority of infiltrative inflammatory cells in the pulmonary interstitium 396 are CD8⁺ T cells that play an important role in virus clearance as well as in immune-mediated 397 injury 17 . After comparing T cell-deficient mice and B cell-deficient mice, it is found that T 398 cells are able to survive and kill virus-infected cells in the MERS-CoV infected lung¹⁸. These 399 data highlight the importance of T lymphocytes, in particular, CD4⁺ T cells but not B cells in 400 controlling and finetuning the pathogenesis and outcomes of SARS-CoV and MERS-CoV 401 infection.

402 Hin Chu et al demonstrated that MERS-CoV but not SARS-CoV can efficiently infect T cells 403 from the peripheral blood and from human lymphoid organs, and induce apoptosis in T cells, 404 which involves the activation of both the extrinsic and intrinsic apoptosis pathways. This may 405 partly explain the lymphopenia observed in MERS-CoV-infected patients¹⁹. The inability of 406 the SARS-CoV to infect T cells may be ascribed to the lower expression of the SARS-CoV 407 receptor, angiotensin-converting enzyme 2 expression (ACE2) in T cells^{15,19}. Several recent 408 structural analyses predict that SARS-CoV-2 also uses ACE2 as its host receptor ²⁰. Therefore, 409 these findings indicate that T cells might not be susceptible to SARS-CoV-2 infection and 410 warrants further investigation. Nevertheless, similar to SARS-CoV-2 infection, SARS-CoV 411 can also significantly decrease peripheral CD4⁺ and CD8⁺ T lymphocyte subsets and it was 412 related to the onset of illness²¹. Several potential mechanisms may be involved, including the 413 development of auto-immune antibodies or immune complexes triggered by viral infection, 414 directly infecting and promoting the growth inhibition and apoptosis of hematopoietic stem 415 and progenitor cells, as well as the use of glucocorticoids, which may account for the decrease 416 of lymphocytes in some SARS patients²².

417 Although nothing is known about mechanism underlying the lymphopenia caused by 418 SARS-CoV-2 infection, in this present study, some patients were administered 419 methylprednisolone, the average dosage was a bit higher in severe cases (40-80mg once a day) 420 than moderate cases (20-40mg once a day). Since corticosteroids have a profound effect on 421 circulating T lymphocytes, which may involve their movement out of the intra-vascular

422 compartment²³. In this study, we could not exclude the possibility that some of the
423 lymphopenia may be associated with use of steroids, but it does not account for all the cases,
424 and certainly not for the lymphopenia at the initial presentation. Further research is required
425 to determine the effects of corticosteroid on lymphocytes in the patient with COVID-19.

426 Our study has some limitations. First of all, we mainly evaluated the number of T cell subsets 427 and NK cells as well as their IFN- γ production, the function of these cells, and the role of 428 activated macrophages and lymphocytes infiltrating lung parenchyma remain unclear. Second, 429 this study only included a small number of patients, thus the results should be interpreted with 430 caution, and statistical non-significance may not rule out difference between severe and 431 moderate cases. Third, since data regarding the viremia profile of SARS-CoV-2 are not 432 available, further studies are needed to investigate the correlation between the virus load 433 kinetics and the dynamics of cellular immune responses. Clarification of these questions will 434 allow further dissection of the complex SARS-CoV-2 pathogenesis, with potential 435 implications for the development of therapeutics and vaccines.

In conclusion, the SARS-CoV-2 infection may affect primarily T lymphocytes, especially CD4⁺T cells, resulting in significant decrease in number as well as IFN-γ production, which may be associated with disease severity. Together with clinical characteristics, early immunologic indicators including diminished T lymphocytes and elevated cytokines may serve as potential markers for prognosis in COVID-19. Gaining a deeper understanding of the factors that influence lymphocytes particularly CD4⁺T cell counts and their decrease in patients with SARS-CoV-2 infection is of importance for clinical management of COVID-19.

444 Contributors

- 445 QN designed the study and had full access to all data in the study and take responsibility for
- the integrity of data and the accuracy of the data analysis.
- 447 GC and DW contributed to patient recruitment, data collection, data analysis, data
- 448 interpretation, literature search, and writing of the manuscript.
- 449 WG and YC had roles in patient recruitment, data collection, and clinical management.
- 450 DH, HW, TW and XZ had roles in the experiments, data collection, data analysis, and data
- 451 interpretation.
- 452 All authors contributed to data acquisition, data analysis, or data interpretation, and reviewed
- 453 and approved the final version of the manuscript.

454

455 Declaration of interests

- 456 All authors declare no competing interests.
- 457

458 Acknowledgments

- 459 This work is funded by grants from Tongji Hospital for Pilot Scheme Project, and partly
- 460 supported by the Chinese National Thirteenth Five Years Project in Science and Technology
- 461 (2017ZX10202201).

463 Reference

- 464 1. Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients
- with severe acute respiratory syndrome. *N Engl J Med* 2003; **348**(20): 1967-76.
- 466 2. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a
- 467 novel coronavirus from a man with pneumonia in Saudi Arabia. *N Engl J Med* 2012; **367**(19):
- 468 1814-20.
- 469 3. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in
- 470 China, 2019. *N Engl J Med* 2020.
- 471 4. Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. *Viruses* 2020;
- 472 **12**(2).
- 473 5. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel
 474 Coronavirus-Infected Pneumonia. *N Engl J Med* 2020.
- 475 6. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019
- 476 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet
- 477 2020.
- 478 7. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
- 479 coronavirus in Wuhan, China. *Lancet* 2020.
- 480 8. WHO. Clinical management of severe acute respiratory infection when Novel coronavirus
- 481 (nCoV) infection is suspected: interim guidance. Jan 11, 2020.
- 482 https://www.who.int/internalpublications-
- 483 detail/clinical-management-of-severe-acute-respiratoryinfection-when-novel-coronavirus-(nco
- 484 v)-infection-is-suspected (accessed Jan 20, 2020).

485	9. Nanshan Chen MZ, Xuan Dong, Jieming Qu, Fengyun Gong, Yang Han, Yang Qiu, Jingli
486	Wang, Ying Liu, Yuan Wei, Jia'an Xia, Ting Yu,, Xinxin Zhang LZ. Epidemiological and clinical
487	characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a
488	descriptive study. <i>Lancet</i> 2020.
489	10. Arruvito L, Payaslian F, Baz P, et al. Identification and clinical relevance of naturally
490	occurring human CD8+HLA-DR+ regulatory T cells. <i>J Immunol</i> 2014; 193 (9): 4469-76.
491	11. Xu X, Gao X. Immunological responses against SARS-coronavirus infection in humans.
492	<i>Cell Mol Immunol</i> 2004; 1 (2): 119-22.
493	12. Frasca L PC, Piccolella E. CD4+ T cells orchestrate both amplification and deletion of
494	CD8+ T cells. Crit Rev Immunol. 1998;18(6):569-94.
495	13. Taylor GA, Feng CG, Sher A. p47 GTPases: regulators of immunity to intracellular
496	pathogens. <i>Nat Rev Immunol</i> 2004; 4 (2): 100-9.
497	14. Arabi YM, Arifi AA, Balkhy HH, et al. Clinical course and outcomes of critically ill patients
498	with Middle East respiratory syndrome coronavirus infection. Ann Intern Med 2014; 160(6):
499	389-97.
500	15. Ying T, Li W, Dimitrov DS. Discovery of T-Cell Infection and Apoptosis by Middle East
501	Respiratory Syndrome Coronavirus. <i>J Infect Dis</i> 2016; 213 (6): 877-9.
502	16. Chen J, Lau YF, Lamirande EW, et al. Cellular immune responses to severe acute
503	respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T
504	cells are important in control of SARS-CoV infection. <i>J Virol</i> 2010; 84 (3): 1289-301.
505	17. Zhao JM, Zhou GD, Sun YL, et al. [Clinical pathology and pathogenesis of severe acute
506	respiratory syndrome]. <i>Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi</i> 2003; 17 (3):

507 217-21.

- 508 18. Zhao J, Li K, Wohlford-Lenane C, et al. Rapid generation of a mouse model for Middle
- 509 East respiratory syndrome. Proc Natl Acad Sci U S A 2014; 111(13): 4970-5.
- 510 19. Chu H, Zhou J, Wong BH, et al. Middle East Respiratory Syndrome Coronavirus
- 511 Efficiently Infects Human Primary T Lymphocytes and Activates the Extrinsic and Intrinsic
- 512 Apoptosis Pathways. *J Infect Dis* 2016; **213**(6): 904-14.
- 513 20. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus
- 514 from Wuhan: An analysis based on decade-long structural studies of SARS. *J Virol* 2020.
- 515 21. He Z ZC, Dong Q, Zhuang H, Song S, Peng G, Dwyer DE. Effects of severe acute
- 516 respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their
- 517 subsets. Int J Infect Dis 2005; 9(6):323-30.
- 518 22. Yang M, Li CK, Li K, et al. Hematological findings in SARS patients and possible
- 519 mechanisms (review). *Int J Mol Med* 2004; **14**(2): 311-5.
- 520 23. Cupps TR, Fauci AS. Corticosteroid-mediated immunoregulation in man. Immunol Rev
- 521 1982; **65**: 133-55.
- 522

524 Figure legend

- 525 Figure 1: Computed tomography of the chest of patients with COVID-19
- 526 Chest CT axial view lung window from a 62-year-old female with severe COVID-19 showing 527 bilateral ground-glass opacity and subsegmental areas of consolidation on day 6 after 528 symptom onset (A), and typical presentation of a "white lung" appearance with bilateral 529 multiple lobular and subsegmental areas of consolidation on day 8 after symptom onset (B). 530 Chest CT axial view lung window from a 32-year-old male with moderate COVID-19 531 showing bilateral ground-glass opacity on day 7 after symptom onset (C), and resolved 532 bilateral ground-glass opacity on day 11 after symptom onset (D). 533 534 Figure 2: Number of immune cell subsets and proportion of IFN- γ expression in patients with 535 COVID-19 536 (A) Flow cytometry staining of natural killer (NK) cells, CD4⁺T cells, CD8⁺T cells and Treg 537 as well as production of IFN- γ by CD4⁺T cells, CD8⁺T cells and NK cells from a 538 representative patient. 539 (B) A series of comparisons of absolute number of total T&B lymphocytes, CD4⁺T cells, 540 CD8⁺T cells and NK cells between severe cases and moderate cases. Data are expressed as 541 mean \pm SEM. 542 (C) A series of comparisons of production of IFN- γ by CD4⁺T cells, CD8⁺T cells and NK 543 cells between severe cases and moderate cases. Data are expressed as mean \pm SEM.
- 544

	All patients	severe cases	moderate cases	P value
	(n=21)	(n=11)	(n=10)	
Characteristics				
Males, n (%)	17 (81.0%)	10 (90.9%)	7 (70.0%)	0.31
Age, yrs	56.3 (14.3)	63.9 (9.6)	51.4 (13.7)	0.038
>50	15 (71.4%)	10 (90.9%)	5 (50.0%)	0.043
Huanan seafood market	4 (19.4%)	1 (9.1%)	3 (30.0%)	0.31
exposure, n (%)				
Any comorbidity, n (%)	7 (33.3%)	5 (45.5%)	2 (20.0%)	0.36
Hypertension, n (%)	5 (23.8%)	4 (19.0%)	1 (10.0%)	0.31
Diabetes, n (%)	3 (14.3%)	2 (18.2%)	1 (10.0%)	1.00
Signs and symptoms				
Fever, n/N (%)	20/20 (100%)	10/10 (100%)	10/10 (100%)	NA
Highest temperature, °C	38.8 (0.54)	38.8 (0.69)	38.8 (0.26)	0.85
38.1-39.0 °C, n/N (%)	12/19 (63.2%)	5/9 (55.6%)	7/10 (70.0%)	0.52
>39.0 °C, n/N (%)	7/19 (36.8%)	4/9 (44.4%)	3/10 (30.0%)	
Cough, n/N (%)	16/20 (80.0%)	7/10 (70.0%)	9/10 (90.0%)	0.58
Fatigue, n/N (%)	17/20 (85.0%)	10/10	7/10 (70.0%)	0.21
		(100.0%)		
Myalgia, n/N (%)	8/20 (40.0%)	5/10 (50.0%)	3/10 (30.0%)	0.65
Sputum production, n/N	5/20 (25%)	2/10 (20.0%)	3/10 (30.0%)	1.00
(%)				
Headache, n/N (%)	2/20 (10.0%)	1/10 (10.0%)	1/10 (10.0%)	1.00
Diarrhea, n/N (%)	4/20 (20.0%)	1/10 (10.0%)	3/10 (30.0%)	0.58
Chest tightness, n/N (%)	11/20 (55.0%)	8/10 (80.0%)	3/10 (30.0%)	0.07
Coma, n (%)	1 (4.8%)	1 (9.1%)	0 (0.0%)	1.00
Dyspnea, n (%)	11 (52.4%)	11 (100.0%)	0 (0.0%)	0.000
Days from illness onset	8.6 (3.9)	8.6 (3.9)	NA	NA

545 Table 1 Demographics and baseline characteristics of patients with COVID-19

to dyspnea							
Systolic pressure, mm	125.7 (19.6)	131.5 (21.5)	119.3 (15.0)	0.17			
Hg							
Heart rate, bpm	90.0 (14.8)	90.5 (18.6)	89.6 (8.9)	0.90			
Respiratory rate, per	24.0 (5.6)	27.3 (6.1)	20.4 (0.6)	0.003			
min							
>24 breaths per min,	8 (38.1%)	8 (72.7%)	0 (0.0%)	0.001			
n (%)							
PaO2/FiO2	220.2 (142.5)	122.9 (45.6)	366.2 (110)	0.002			
>300, n/N (%)	3/10 (30.0%)	0/6 (0.0%)	3/4 (75%)	0.011			
200-300, n/N (%)	2/10 (20.0%)	1/6 (16.7%)	1/4 (25%)				
100-200, n/N (%)	2/10 (20.0%)	2/6 (33.3%)	0/4 (0.0%)				
≤100, n/N (%)	3/10 (30.0%)	3/6 (50.0%)	0/4 (0.0%)				

546 Data are mean (S.D.), n (%), or n/N (%), where N is the total number of patients with

547 available data. p values comparing severe cases and moderate cases are from χ^2 test, Fisher's

548 exact test, or Mann-Whitney U test.

	All patients	severe cases	moderate cases	P value
	(n=21)	(n=11)	(n=10)	
White blood cell	7.0 (3.6)	9.2 (3.6)	4.7 (1.5)	0.002
count, $\times 10 \Box/L$				
<4, n (%)	3 (14.3%)	0 (0.0%)	3 (30.0%)	0.017
4-10, n (%)	15 (%)	8 (%)	7 (70.0%)	
≥10, n (%)	3 (%)	3 (%)	0 (0.0%)	
Neutrophil count, \times	5.7 (3.8)	8.0 (3.7)	3.1 (1.3)	0.001
10□/L				
Lymphocyte count, \times	0.9 (0.4)	0.7 (0.3)	1.1 (0.3)	0.048
10□/L				
<0.8, n (%)	9 (42.9%)	8 (72.7%)	1 (10.0%)	0.008
Hemoglobin, g/L	137.0 (17.4)	138.1 (15.9)	135.8 (18.4)	0.78
Platelet count, ×	162.7 (45.0)	164.2 (45.8)	161.0 (44.2)	0.88
10□/L				
<100, n (%)	1 (4.8%)	0 (0.0%)	1 (10.0%)	0.48
Alanine	30.0 (16.5)	41.4 (14.9)	17.6 (5.8)	0.0002
aminotransferase,				
U/L				
Aspartate	38.2 (24.6)	51.0 (28.3)	24.2 (4.1)	0.011
aminotransferase,				
U/L				
>40, n (%)	6 (28.6%)	5 (45.5%)	0 (0.0%)	0.035
Albumin, g/L	34.4 (5.7)	31.5 (5.5)	37.6 (4.0)	0.013
Total bilirubin,	9.8 (5.6)	11.2 (6.4)	8.2 (3.8)	0.24
mmol/L				
Blood urea nitrogen,	6.1 (3.3)	7.7 (3.7)	4.2 (1.3)	0.014

550 Table 2 Laboratory findings and chest CT images of patients with COVID-19 on

551

admission

mmol/l							
Creatinine, µmol/L	82.4 (30.3)	90.7 (38.5)	73.3 (11.6)	0.21			
Creatine kinase, U/L	153.7 (123.1)	208.3 (122.4)	106.9 (102.8)	0.16			
Lactate	408.1 (231.0)	567.2 (217.1) 234.4 (46.7)		0.0002			
dehydrogenase, U/L							
Prothrombin time, s	13.8 (1.0)	14.1 (0.9)	13.4 (1.0)	0.15			
Activated partial	40.0 (6.5)	36.2 (5.8)	44.6 (3.7)	0.002			
thromboplastin time,							
S							
D-dimer, µg/mL	4.0 (7.0)	8.2 (9.0)	0.4 (0.3)	0.025			
Procalcitonin, ng/mL	0.3 (0.5)	0.5 (0.6)	0.1 (0.1)	0.073			
<0.1, n/N (%)	7/18 (38.9)	0/10 (0.0%)	7/8 (87.5%)	0.002			
0.1-0.25, n/N (%)	6/18 (33.3%)	6/10 (60.0%)	0/8 (0.0%)				
0.25-0.5, n/N (%)	2/18 (11.1%)	1/10 (10.0%)	1/8 (12.5%)				
≥0.5, n/N (%)	3/18 (16.7%)	3/10 (30.0%)	0/8 (0.0%)				
High-sensitivity	97.5 (66.4)	135.2 (52.4)	51.4 (50.8)	0.003			
C-reactive protein,							
mg/L							
>60, n/N (%)	14/20 (70%)	11/11 (100.0)	3/9 (33.3%)	0.002			
Ferritin, µg/L	1284.8 (934)	1734.4 (585.6)	880.2 (1001.0)	0.049			
>800, n/N (%)	12/19 (63.2%)	9/9 (100.0%)	3/10 (30.0%)	0.003			
Bilateral	17/21 (81.0%)	10/11 (90.9%)	7/10 (70%)	0.31			
involvement of chest	involvement of chest						
computed							
tomography scan on							
admission							
Data are mean (S.D.)	Data are mean (S.D.) or n/N (%), where N is the total number of patients with available data.						

553 p values comparing severe cases and moderate cases are from χ^2 , Fisher's exact test, or 554 Mann-Whitney U test.

	All patients	severe cases	moderate	Р	Normal
	(n=21)	(n=11)	cases	value	range
			(n=10)		
Plasma cytokines					
IL-1β increased, n/N	1/16 (6.2%)	1/9 (11.1%)	0/7 (0.0%)	1.00	<5
(%)					
IL-2R, U/mL	869.6 (486.2)	1202.4	441.7	0.0004	223-710
		(380.2)	(169.9)		
increased, n/N	9/16 (56.3%)	8/9 (88.9%)	1/7 (14.3%)	0.009	
(%)					
IL-6, pg/mL	51.2 (59.4)	73.8 (67.9)	18.8 (13.9)	0.066	<7
increased, n/N	13/16 (81.3%)	8/9 (88.9%)	5/7 (71.4%)	0.55	
(%)					
IL-8, pg/mL	45.6 (56.2)	61.8 (67.1)	24.7 (25.4)	0.21	<62
increased, n/N	3/16 (18.8%)	2/9 (22.2%)	1/7 (14.3%)	1.00	
(%)					
IL-10, pg/mL	9.0 (2.9)	10.9 (1.8)	6.6 (2.1)	0.001	<9.1
increased, n/N	9/16 (56.3%)	7/9 (77.8%)	2/7 (28.6%)	0.12	
(%)					
TNF-α, pg/mL	9.4 (3.0)	10.9 (3.0)	7.5 (1.6)	0.023	<8.1
increased, n/N	11/16 (68.8%)	8/9 (88.9%)	3/7 (42.9%)	0.11	
(%)					
>10 pg/mL, n/N	7/16 (43.8%)	7/9 (77.8%)	0/7 (0.0%)	0.003	
(%)					
Peripheral immune					
cell subsets					
Total T lymphocytes	61.6 (10.5)	56.1 (9.5)	69 (6.3)	0.020	50-84
(%)					

556 Table 3 Immunologic features of patients with COVID-19

Total T lymphocytes		479.9 (259.8)	332.5	676.5	0.011	955-2860
count, $\times 10^6/L$			(207.9)	(179.7)		
decreased,	n/N	13/14 (92.9%)	8/8	5/6 (83.3%)	0.43	
(%)			(100.0%)			
<400, n/N (%))	6/14 (42.9%)	6/8 (75.0%)	0/6 (0.0%)	0.010	
Total B lymphod	cytes	20.3 (12.7)	26.5 (13.1)	12.0 (5.3)	0.036	5-18
(%)						
increased,	n/N	7/14 (50.0%)	6/8 (75.0%)	1/6 (16.7%)	0.10	
(%)						
Total B lymphod	cytes	144.6 (95.6)	165.1	117.2 (50.2)	0.39	90-560
$\text{count,} \times 10^6 / \text{L}$			(114.6)			
decreased,	n/N	4/14 (28.6%)	3/8 (37.5%)	1/6 (16.7%)	0.58	
(%)						
CD4 ⁺ T cells, (%)	34.7 (8.4)	33.4 (8.8)	36.3 (7.5)	0.56	27-51
CD4 ⁺ T cells cou	nt, ×	260 (138.9)	185.6	359.2	0.018	550-1440
10 ⁶ /L			(101.4)	(118.7)		
decreased,	n/N	14/14	8/8	6/6	NA	
(%)		(100.0%)	(100.0%)	(100.0%)		
CD8 ⁺ T cells, (%)	23.0 (8.3)	19.6 (6.5)	27.5 (8.4)	0.093	15-44
CD8 ⁺ T cells cou	nt, ×	187.6 (129.3)	124.3	272.0	0.035	320-1250
10 ⁶ /L			(107.9)	(105.0)		
decreased,	n/N	12/14 (85.7%)	7/8 (87.5%)	5/6 (83.3%)	1.00	
(%)						
<150, n/N (%))	6/14 (42.9%)	6/8 (75.0%)	0/6 (0.0%)	0.010	
NK cells, (%)		16.9 (9.6)	15.7 (9.9)	18.5 (8.9)	0.62	7-40
NK cells coun	t, ×	134.7 (104.7)	106.1	172.8 (67.7)	0.27	150-1100
10 ⁶ /L			(117.7)			
decreased,	n/N	8/14 (57.1%)	6/8 (75.0%)	2/6 (33.3%)	0.28	
(%)						

<77, n/	/N (%)	6/14 (42.9%)	6/8 (75.0%)	0/6 (0.0%)	0.010	
CD28 ⁺ CI	D4 ⁺ T cells/	97.7 (1.8)	97.7 (1.5)	97.7 (2.2)	0.99	84.11-100.00
CD4 ⁺ T, %	6					
CD28 ⁺ CI	D8 ⁺ T cells/	60.9 (17.7)	53.8 (19.8)	69.9 (8.4)	0.22	48.04-77.14
CD8 ⁺ T, 9	6					
HLA-DR	⁺ CD8 ⁺ T	41.5 (12.4)	46.8 (6.9)	34.7 (14.3)	0.19	20.73-60.23
cells/ CD	98 ⁺ T, %					
>35%,	n/N (%)	6/9 (66.7%)	5/5 (100%)	1/4 (25.0%)	0.048	
CD45RA	+CD4+T	36.8 (11.0)	39.1 (12.5)	33.8 (7.6)	0.54	29.41-55.41
cells/ CD	4 ⁺ T, %					
CD45RO	⁺ CD4 ⁺ T	63.2 (11.0)	60.9 (12.5)	66.2 (7.6)	0.54	44.44-68.94
cells/ CD	94 ⁺ T, %					
Treg, %		3.98 (1.4)	3.9 (1.7)	4.0 (0.5)	0.92	5.36-6.30
CD45RA	⁺ Treg, %	0.76 (0.4)	0.5 (0.3)	1.1 (0.2)	0.019	2.07-4.55
CD45RO	⁺ Treg, %	3.2 (1.3)	3.5 (1.7)	2.9 (0.5)	0.62	1.44-2.76
IFN-γ	expressing	19.4 (8.4)	14.6 (5.5)	23.6 (8.4)	0.063	14.54-36.96
CD4 ⁺ T cells, %						
IFN-γ	expressing	48.8 (9.7)	46.6 (10.7)	50.7 (8.3)	0.49	34.93-87.95
CD8 ⁺ T cells, %						
IFN-γ	expressing	71.5 (11.0)	67.4 (8.8)	75.0 (11.4)	0.25	61.2-92.65
NK cells, %						

557 Data are mean (S.D.) or n/N (%), where N is the total number of patients with available data.

558 p values comparing severe cases and moderate cases are from χ^2 , Fisher's exact test, or 559 Mann-Whitney U test.

mediaxiv preprint doi: https://doi.org/10.1104/2020102.16.20023903; this version posted February 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is me author/funder, who has granted medRxiv a license to display the preprint in perpetuity.







C Case 2 first chest CT





D Case 2 second chest CT





